Bio-Rad Laboratories (BIO) Projected to Post Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, July 31st. Analysts expect Bio-Rad Laboratories to post earnings of $1.98 per share and revenue of $614.82 million for the quarter. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The firm's revenue was down 4.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.30 EPS. On average, analysts expect Bio-Rad Laboratories to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Bio-Rad Laboratories Stock Up 0.8%

BIO traded up $2.02 during trading on Friday, hitting $264.08. The company had a trading volume of 247,163 shares, compared to its average volume of 246,801. The company has a market capitalization of $7.19 billion, a PE ratio of -3.47 and a beta of 0.95. Bio-Rad Laboratories has a one year low of $211.43 and a one year high of $387.99. The firm's 50-day moving average price is $239.05 and its 200 day moving average price is $263.47. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Empowered Funds LLC boosted its position in shares of Bio-Rad Laboratories by 14.8% during the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company's stock worth $377,000 after acquiring an additional 199 shares in the last quarter. Royal Bank of Canada increased its holdings in Bio-Rad Laboratories by 25.2% in the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company's stock valued at $7,382,000 after purchasing an additional 6,100 shares during the period. Jane Street Group LLC raised its stake in Bio-Rad Laboratories by 95.3% during the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company's stock worth $9,105,000 after buying an additional 18,239 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Bio-Rad Laboratories by 45.6% during the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company's stock worth $25,575,000 after buying an additional 32,874 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BIO. Citigroup cut their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. UBS Group cut their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wall Street Zen cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 13th. Wells Fargo & Company cut their price target on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a research report on Monday, June 9th. Finally, Royal Bank Of Canada cut their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $324.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.